Affiliation:
1. From the Divisions of Hematology and Nuclear Medicine, Mayo Clinic, Rochester, MN.
Abstract
PURPOSE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceutical, San Diego, CA) is an effective therapy for patients with relapsed B-cell non-Hodgkin’s lymphoma. The predominant toxicity of90Y ibritumomab tiuxetan has been myelosuppression, and concern has been expressed about the tolerability of further treatment after this therapy. The goal of this analysis was to evaluate the therapy given to patients who relapsed after90Y ibritumomab tiuxetan.PATIENTS AND METHODS: A retrospective analysis was performed on 58 patients treated at a single institution on five separate protocols that used90Y ibritumomab tiuxetan 0.4 mCi/kg. All patients had experienced disease progression after90Y ibritumomab tiuxetan treatment and received subsequent therapy. The toxicity seen in this cohort of patients with subsequent treatment regimens was analyzed and compared with that of control groups who did not receive90Y ibritumomab tiuxetan.RESULTS: The median number of subsequent therapies was two (range, one to seven). Sixteen (28%) of the 58 patients received growth factor support with subsequent chemotherapy, and two patients were treated with reduced doses because of persistent pancytopenia. Eight patients subsequently had an autologous stem-cell transplantation with stem cells collected after90Y ibritumomab tiuxetan therapy. Excluding patients hospitalized at the time of transplantation, 13 patients were hospitalized for neutropenic fever, thrombocytopenia, or both. When compared to patients who did not receive90Y ibritumomab tiuxetan, there was no significant difference in toxicity.CONCLUSION: We conclude that chemotherapy or autologous stem-cell transplantation after prior therapy with90Y ibritumomab tiuxetan is feasible and reasonably well tolerated. The toxicity with subsequent therapy seems similar to that in patients not treated with90Y ibritumomab tiuxetan.
Publisher
American Society of Clinical Oncology (ASCO)
Reference19 articles.
1. Valentine MA, Meier KE, Rossie S, et al: Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. J Biol Chem 264: 11282,1989-11287,
2. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.
3. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation
4. Tedder TF, Boyd AW, Freedman AS, et al: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135: 973,1985-979,
5. Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献